Firms unite to develop antibiotics against drug-resistant bacteria

09/12/2013 | Pharmaceutical Business Review Online

Swiss firm Debiopharm Group and TCG Lifesciences, a contract research services company, agreed to jointly develop antibiotics against drug-resistant bacteria. Debiopharm will fund the collaboration and share its drug development expertise. TCG's "extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348," Debiopharm President Rolland-Yves Mauvernay said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA